Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance
S Chou - Antimicrobial agents and chemotherapy, 2015 - Am Soc Microbiol
Letermovir (LMV) is an experimental cytomegalovirus terminase inhibitor undergoing phase
3 clinical trials. Viral mutations have been described at UL56 codons 231 to 369 that confer …
3 clinical trials. Viral mutations have been described at UL56 codons 231 to 369 that confer …
Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure
T Goldner, C Hempel… - Antimicrobial agents …, 2014 - Am Soc Microbiol
Letermovir is a novel antiviral compound currently in clinical development for the prevention
of human cytomegalovirus (HCMV) infections. In contrast to all currently approved anti …
of human cytomegalovirus (HCMV) infections. In contrast to all currently approved anti …
A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance
S Chou - Antiviral research, 2017 - Elsevier
Letermovir is a human cytomegalovirus (CMV) terminase inhibitor that was clinically
effective in a Phase III prevention trial. In vitro studies have shown that viral mutations …
effective in a Phase III prevention trial. In vitro studies have shown that viral mutations …
New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir
S Chou, LE Satterwhite, RJ Ercolani - Antimicrobial agents and …, 2018 - Am Soc Microbiol
Letermovir is a human cytomegalovirus (CMV) terminase inhibitor recently approved as
prophylaxis in stem cell transplant recipients. In further studies of emerging drug resistance …
prophylaxis in stem cell transplant recipients. In further studies of emerging drug resistance …
Comparison of cytomegalovirus terminase gene mutations selected after exposure to three distinct inhibitor compounds
S Chou - Antimicrobial agents and chemotherapy, 2017 - Am Soc Microbiol
Letermovir, GW275175X (a benzimidazole), and tomeglovir (Bay38-4766) are chemically
unrelated human cytomegalovirus (CMV) terminase complex inhibitors that have been …
unrelated human cytomegalovirus (CMV) terminase complex inhibitors that have been …
Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228)
P Lischka, D Michel… - The Journal of infectious …, 2016 - academic.oup.com
Background The efficacy of different letermovir (AIC246, MK8228) doses (60, 120, and 240
mg/day) against human cytomegalovirus (HCMV) was evaluated in a recent phase 2b dose …
mg/day) against human cytomegalovirus (HCMV) was evaluated in a recent phase 2b dose …
Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance
The prevention and treatment of human cytomegalovirus (HCMV) infections is based on the
use of antiviral agents that currently target the viral DNA polymerase and that may cause …
use of antiviral agents that currently target the viral DNA polymerase and that may cause …
Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus
DP Melendez, RR Razonable - Infection and drug resistance, 2015 - Taylor & Francis
Infection with cytomegalovirus is prevalent in immunosuppressed patients. In solid organ
transplant and hematopoietic stem cell transplant recipients, cytomegalovirus infection is …
transplant and hematopoietic stem cell transplant recipients, cytomegalovirus infection is …
[HTML][HTML] Letermovir treatment of human cytomegalovirus infection antiinfective agent
PS Verghese, MR Schleiss - Drugs of the Future, 2013 - ncbi.nlm.nih.gov
Novel therapies are urgently needed for the management of cytomegalovirus (CMV) disease
in high-risk patients. Currently licensed agents target the viral DNA polymerase, and …
in high-risk patients. Currently licensed agents target the viral DNA polymerase, and …
Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance
S Chou - Antiviral research, 2020 - Elsevier
Cytomegalovirus (CMV) drug resistance mutation maps are updated with recent information
for polymerase inhibitors, the terminase inhibitor letermovir and the UL97 kinase inhibitor …
for polymerase inhibitors, the terminase inhibitor letermovir and the UL97 kinase inhibitor …